ReNeuron Group PLC - Brigend, Wales-based stem cell and exosomes technology company - Generates in vivo data to exemplify cellular and tissue targeting capabilities of exosomes, produced from its multiple conditionally immortalised producer cell lines. Exosomes are extracellular vesicles which carry nucleic acids, proteins, lipids and metabolites. Typically, they play important roles in immune response, tumour progression, and neurodegenerative diseases.
ReNeuron says it will now look at broadening its capabilities, more specifically focusing on the functional delivery of specific payloads.
Chief Scientific Officer Randolph Corteling says: "I am pleased to confirm that over the last six months we have generated comparative in vivo data demonstrating distinct organ and cellular targeting capabilities of our proprietary stem-cell derived exosomes, which differentiates our CustomEX platform from that of our competitors."
Current stock price: 9.01 pence, down 2.6% on Monday
12-month change: down 68%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Reneuron (RENE)